Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsReceivablesReceivables - NetShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sanofi (SNY) Raw Materials (2016 - 2018)

Historic Raw Materials for Sanofi (SNY) over the last 4 years, with Q4 2018 value amounting to $1.2 billion.

  • Sanofi's Raw Materials rose 238.09% to $1.2 billion in Q4 2018 from the same period last year, while for Dec 2018 it was $1.2 billion, marking a year-over-year increase of 238.09%. This contributed to the annual value of $1.2 billion for FY2018, which is 674.17% up from last year.
  • Latest data reveals that Sanofi reported Raw Materials of $1.2 billion as of Q4 2018, which was up 238.09% from $1.1 billion recorded in Q4 2017.
  • Over the past 5 years, Sanofi's Raw Materials peaked at $1.2 billion during Q4 2018, and registered a low of $1.0 billion during Q4 2016.
  • Its 4-year average for Raw Materials is $1.1 billion, with a median of $1.1 billion in 2015.
  • As far as peak fluctuations go, Sanofi's Raw Materials tumbled by 262.43% in 2016, and later skyrocketed by 1054.32% in 2017.
  • Sanofi's Raw Materials (Quarter) stood at $1.1 billion in 2015, then decreased by 2.62% to $1.0 billion in 2016, then increased by 10.54% to $1.1 billion in 2017, then grew by 2.38% to $1.2 billion in 2018.
  • Its Raw Materials was $1.2 billion in Q4 2018, compared to $1.1 billion in Q4 2017 and $1.0 billion in Q4 2016.